These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 23830726)

  • 1. Progressive vigabatrin-associated visual field loss and the importance of continuing assessment of risks and benefit of epilepsy treatments.
    Treiman DM
    Epilepsy Res; 2013 Aug; 105(3):261. PubMed ID: 23830726
    [No Abstract]   [Full Text] [Related]  

  • 2. Is reduced ornithine-δ-aminotransferase activity the cause of vigabatrin-associated visual field defects?
    Sorri I; Brigell MG; Mályusz M; Mahlamäki E; de Meynard C; Kälviäinen R
    Epilepsy Res; 2010 Nov; 92(1):48-53. PubMed ID: 20850272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the risk of vigabatrin-attributed visual field loss lower in infancy than in later life?
    Riikonen R
    Epilepsia; 2009 Aug; 50(8):2005-6. PubMed ID: 19682035
    [No Abstract]   [Full Text] [Related]  

  • 4. Evolution of visual field loss over ten years in individuals taking vigabatrin.
    Clayton LM; Stern WM; Newman WD; Sander JW; Acheson J; Sisodiya SM
    Epilepsy Res; 2013 Aug; 105(3):262-71. PubMed ID: 23541931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Influence of vigabatrin on visual fields and electrophysiological tests in patients with epilepsy].
    Mrugacz M; Bakunowicz-Łazarczyk A
    Klin Oczna; 2003; 105(5):326-8. PubMed ID: 14746191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visual field defects associated with vigabatrin therapy.
    Lawden MC; Eke T; Degg C; Harding GF; Wild JM
    J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):716-22. PubMed ID: 10567485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vigabatrin associated visual field constriction.
    Acheson JF
    J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):707-8. PubMed ID: 10567482
    [No Abstract]   [Full Text] [Related]  

  • 8. [Changes in visual field of a child treatment with vigabatrin for 2 years].
    Mrugacz M; Bakunowicz-Łazarczyk A
    Klin Oczna; 2003; 105(5):313-4. PubMed ID: 14746187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recovery of visual field constriction following discontinuation of vigabatrin.
    Krakow K; Polizzi G; Riordan-Eva P; Holder G; MacLeod WN; Fish DR
    Seizure; 2000 Jun; 9(4):287-90. PubMed ID: 10880291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed, rapid visual field loss in a patient after ten years of vigabatrin therapy.
    Clayton LM; Duncan JS; Sisodiya SM; Acheson JF
    Eye (Lond); 2010 Jan; 24(1):185-6. PubMed ID: 19373265
    [No Abstract]   [Full Text] [Related]  

  • 11. Visual field defect associated with vigabatrin. Many more patients may be affected than were found in study.
    Comaish IF; Gorman C; Galloway NR
    BMJ; 2000 May; 320(7246):1403; author reply 1404. PubMed ID: 10858054
    [No Abstract]   [Full Text] [Related]  

  • 12. [Visual field changes as a side effect of treatment with vigabatrin therapy].
    Kobylański P
    Neurol Neurochir Pol; 2000; 34(3):597-9. PubMed ID: 10979552
    [No Abstract]   [Full Text] [Related]  

  • 13. Visual field constriction on vigabatrin.
    Prescrire Int; 2000 Feb; 9(45):210-1. PubMed ID: 11503799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vigabatrin and epilepsy: further lessons in early childhood.
    Parisi P; Bombardieri R; Curatolo P
    Epilepsia; 2008 Jan; 49(1):177-8. PubMed ID: 18184225
    [No Abstract]   [Full Text] [Related]  

  • 15. Are vigabatrin-associated visual field constrictions asymptomatic?
    Schmidt T; Rüther K; Schmitz B
    J Neurol; 2004 Jul; 251(7):887-8. PubMed ID: 15258797
    [No Abstract]   [Full Text] [Related]  

  • 16. Epilepsy: Vigabatrin treatment and visual field loss.
    Chiron C; Dulac O
    Nat Rev Neurol; 2011 Apr; 7(4):189-90. PubMed ID: 21364521
    [No Abstract]   [Full Text] [Related]  

  • 17. [Vigabatrin: balancing effectiveness vs. (irreversible) visual field loss as a side effect].
    Hardus P; Engelsman M; van Veelen CW; Stilma JS
    Ned Tijdschr Geneeskd; 2000 Oct; 144(43):2066-9. PubMed ID: 11072511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GABA and the ornithine delta-aminotransferase gene in vigabatrin-associated visual field defects.
    Hisama FM; Mattson RH; Lee HH; Felice K; Petroff OA
    Seizure; 2001 Oct; 10(7):505-7. PubMed ID: 11749107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vigabatrin-associated visual field defects in children.
    Russell-Eggitt IM; Mackey DA; Taylor DS; Timms C; Walker JW
    Eye (Lond); 2000 Jun; 14 ( Pt 3A)():334-9. PubMed ID: 11026995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Visual field disturbances in epileptic patients treated with vigabatrin (sevril)].
    Gross-Tsur V; Lahat E; Banin E; Shahar E; Shalev R
    Harefuah; 2002 Mar; 141(3):247-9, 315. PubMed ID: 11944216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.